Current FDA Approval for Lurbinectedin
Lurbinectedin (brand name Zepzelca) is FDA-approved only for metastatic small cell lung cancer (SCLC) in adults with disease progression on or after platinum-based chemotherapy.[1]
Ongoing Clinical Trials in Other Cancers
Trials are testing lurbinectedin in cancers beyond SCLC, including:
- Small cell lung cancer variants like extrapulmonary SCLC.
- Ovarian cancer, often combined with other drugs like doxorubicin or bevacizumab.
- Prostate cancer and endometrial cancer in early-phase studies.
- Triple-negative breast cancer and soft tissue sarcomas.
Most trials focus on relapsed or advanced solid tumors, with phase 2 and 3 data showing some response rates, but no additional approvals yet.[2][3]
Evidence from Preclinical and Early Studies
Lab and animal studies suggest activity against:
- Mesothelioma, neuroblastoma, and Ewing sarcoma due to its DNA repair inhibition mechanism.
- Some lymphomas and leukemias in combination therapies.
These remain experimental; no approvals outside SCLC.[4]
Off-Label Use and Limitations
Off-label prescribing occurs rarely for other thoracic tumors or platinum-resistant cancers, but lacks robust evidence and isn't recommended outside trials. Use in non-cancer diseases like autoimmune conditions has no supporting data.[5]
Barriers to Broader Use
Patent protection lasts until around 2031 in the US (check DrugPatentWatch.com for updates), limiting generic competition but not off-label exploration.[6] Toxicity (e.g., myelosuppression, fatigue) restricts expansion without stronger efficacy data.
[1]: FDA.gov - Zepzelca Approval (https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-lurbinectedin-metastatic-small-cell-lung-cancer)
[2]: ClinicalTrials.gov - Lurbinectedin trials (https://clinicaltrials.gov/search?term=lurbinectedin)
[3]: Trigo et al., Lancet Oncology (2020)
[4]: Kaufman et al., Cancer Research (2019)
[5]: NCCN Guidelines - SCLC (version 2023)
[6]: DrugPatentWatch.com - Lurbinectedin patents (https://www.drugpatentwatch.com/p/tradename/ZEPELCA)